Literature DB >> 28578623

Definition of Type II Endoleak Risk Based on Preoperative Anatomical Characteristics.

Michele Piazza1, Francesco Squizzato1, Tommaso Miccoli1, Sandro Lepidi1, Mirko Menegolo1, Franco Grego1, Michele Antonello1.   

Abstract

PURPOSE: To define the risk for type II endoleak (EII) after endovascular aneurysm repair (EVAR) based on preoperative anatomical characteristics.
METHODS: Between January 2008 and December 2015, 189 patients (mean age 78.4±7.6 years; 165 men) underwent standard EVAR. Mean aneurysm diameter was 5.7±0.7 cm and mean volume 125.2±45.8 cm3. Patients were assigned to the "at-risk" group (n=123, 65%) when at least one of the following criteria was present: patency of a >3-mm inferior mesenteric artery (IMA), patency of at least 3 pairs of lumbar arteries, or patency of 2 pairs of lumbar arteries and a sacral artery or accessory renal artery or any diameter patent IMA; otherwise, patients were entered in the "low-risk" group (n=66, 35%). EII rates and freedom from EII reintervention were compared using Kaplan-Meier curves. Preoperative clinical and anatomical characteristics were evaluated for their association with EII and EII reinterventions using multiple logistic regression analysis; results are presented as the odds ratio (OR) and 95% confidence interval (CI).
RESULTS: Freedom from endoleak was lower in the at-risk group compared with the low-risk group at 36 months after EVAR (p=0.04). Freedom from EII-related reinterventions was significantly lower in the at-risk group (80% vs 100%, p=0.001) at 48 months. Based on the multiple regression analysis, the at-risk group had a higher likelihood of both EII (OR 9.91, 95% CI 2.92 to 33.72, p<0.001) and EII-related reinterventions (OR 9.11, 95% CI 1.06 to 78.44, p=0.04). These criteria had 89.4% (95% CI 83.9% to 93.2%) sensitivity and 48.0% (95% CI 40.7% to 55.3%) specificity for EII; sensitivity and specificity for EII reintervention were 100% (95% CI 93.8% to 100%) and 38.8% (95% CI 31.9% to 46.2%). Within the at-risk group, a sac thrombus volume <35% was an additional predictor for both EII (OR 5.21, 95% CI 1.75 to 15.47, p=0.003) and EII-related reinterventions (OR 8.33, 95% CI 2.20 to 31.51, p<0.002).
CONCLUSION: The selection criteria effectively discriminated between low-risk patients and patients at risk for EII and associated reinterventions. A thrombus volume <35% was an additional predictor for EII and EII-related reintervention among patients at risk. These criteria may be useful for preemptively selecting patients who may benefit from EII prevention procedures or a more aggressive surveillance protocol.

Entities:  

Keywords:  abdominal aortic aneurysm; aneurysm morphology; endoleak; endovascular aneurysm repair; inferior mesenteric artery; intrasac thrombus; lumbar arteries; reintervention; risk assessment; type II endoleak

Mesh:

Year:  2017        PMID: 28578623     DOI: 10.1177/1526602817712511

Source DB:  PubMed          Journal:  J Endovasc Ther        ISSN: 1526-6028            Impact factor:   3.487


  4 in total

Review 1.  Repair of abdominal aortic aneurysms: preoperative imaging and evaluation.

Authors:  David K Hu; George T Pisimisis; Rahul A Sheth
Journal:  Cardiovasc Diagn Ther       Date:  2018-04

2.  Midterm results of periprosthetic coiling embolization in high-risk patients.

Authors:  Xiantao Li; Yanyan Huang; Pingfan Guo
Journal:  J Interv Med       Date:  2019-10-23

3.  The short-term safety and effectiveness of a new distal perforating stent graft in Type B aortic dissection: a retrospective study.

Authors:  Xunqiang Liu; Wenkai Ji; Min Tian; Huanjun Chen; Cuihong Li; Liqiong Zhang; Ying Yang; Jifeng Wang; Min Ji; Chunxin Yang; Enshuai Zhu; Lei Cong; Xili Zhang; Xiaona Zhou; Hailong Liu; Jiaping Wang; Jing Tan; Jinhui Zhang
Journal:  BMC Cardiovasc Disord       Date:  2021-09-21       Impact factor: 2.298

4.  Incidence and Fate of Refractory Type II Endoleak after EVAR: A Retrospective Experience of Two High-Volume Italian Centers.

Authors:  Pasqualino Sirignano; Nicola Mangialardi; Martina Nespola; Francesco Aloisi; Matteo Orrico; Sonia Ronchey; Flavia Del Porto; Maurizio Taurino
Journal:  J Pers Med       Date:  2022-02-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.